The Galician Health Service (Sergas) has signed a collaboration agreement with the Precision Cancer Consortium (PCC), supported by consultancies HiTT and Avalere Health, to accelerate access for Galician patients to comprehensive genomic profiling (CGP) for the diagnosis and treatment of solid tumors. CGP is a key tool in the development of precision oncology, and the project aims to remove barriers and improve processes so that it can be progressively integrated into cancer patient care.
This collaboration forms part of the implementation of the Galician Precision Oncology Strategy (2024), which includes among its objectives facilitating early and equitable access for cancer patients in Galicia to the best molecular diagnostic options and targeted therapies. The project, which will run for four years, will address areas such as healthcare professional training, the establishment of collaborative networks, and the identification of potential economic barriers to CGP. Observers from other autonomous communities in Spain are expected to participate, as the intention is for Galicia’s experience to serve as a blueprint for advancing the consolidation of CGP as a key diagnostic tool in oncology across Spain.
The project being launched in Galicia forms part of a broader initiative by the PCC, a consortium of pharmaceutical companies working on the discovery and development of interventions in the field of precision oncology. The PCC aims to raise awareness of the impact of CGP on improving patient outcomes globally and to facilitate equitable access to this type of testing while addressing the challenges of implementing it within healthcare systems.
In 2024, the PCC selected Spain as a pilot country for establishing CGP as standard practice in diagnosis, conducting an initial in-depth study into the state of precision medicine across seven autonomous communities: Andalusia, Catalonia, Castile and León, the Valencian Community, Galicia, Madrid, and Murcia.
The analysis identified Galicia as the ideal candidate to lead Phase 2 of the project’s scale-up. The region holds a clear leadership position in the development of precision medicine and genomics with initiatives such as the Galician Foundation for Genomic Medicine, the Precisaúde program, the Advanced Therapies Manufacturing Center in Santiago de Compostela, and the forthcoming proton therapy center and benefits from a consensus-backed precision oncology strategy supported by strongly committed stakeholders and experts in the field. This places Galicia in a prime position to positively influence the development of precision oncology and the implementation of CGP in other Spanish regions through the sharing of its experience.